BIOLIFE SOLUTIONS INC: director Ellingson Rachel sold 57,995 shares

What happened

• The filing shows director Rachel Ellingson disposed of 57,995 shares on Oct 6, 2026 in a disposition to the issuer (transaction code D).
• The footnote states the disposition occurred in connection with the closing of a merger: each outstanding BioLife share was converted into $11.25 in cash and 0.1442 shares of Repligen common stock (per the merger agreement dated Jul 21, 2026). Cash consideration totals $652,443.75 and the stock consideration totals 8,362.879 Repligen shares.

Key details

• Transaction date: Oct 6, 2026. Form filed: Oct 8, 2026.
• Transaction code: D (disposition to the issuer) in connection with the First Merger.
• Consideration per share: $11.25 cash and 0.1442 Repligen common shares.
• Total consideration reported (cash): $652,443.75; total Repligen shares resulting: 8,362.879.
• Shares owned after the transaction: not stated in the filed Form 4.
• Relevant footnote: F1 describes the merger conversion and the Merger Agreement dated Jul 21, 2026.
• The filing does not indicate a late filing.

Why it may matter

• This was a disposition tied to a corporate merger—shares were converted into merger consideration rather than sold in the open market.
• The Form 4 reports the mechanics and amounts of the conversion but does not explain motives or company rationale.
• A filing does not show why the insider traded or why the company acted.